Novartis AG has agreed to buy U.S. biotech firm Regulus Therapeutics Inc. in a deal that could be valued at up to $1.7 ...

Novartis has agreed to buy Regulus Therapeutics for up to $1.7 billion, giving the Swiss drugmaker access to an experimental ...

Roughly two years after securing a former Novartis facility in Illinois to support its CAR-T cancer treatments Breyanzi and ...

Swiss pharmaceutical giant Novartis is poised to expand its profile in the San Diego area, announcing plans to acquire ...

After announcing successful trial results for its lead mRNA treatment earlier this year, Regulus Therapeutics agreed to be ...

Despite patent expirations, Novartis' strong cash flow, ongoing buyback, and low-risk profile support our continued buy ...

Novartis has committed another $1.7 billion to its ambition to become a kidney disease leader. The Swiss drugmaker is making ...

Novartis released a more optimistic full-year earnings forecast on Tuesday, citing the strong growth of drugs such as Leqvio, ...

Novartis is buying Regulus for $800 million, picking up the biotech's experimental kidney drug that's based off a ...

Novartis has agreed to acquire US-based Regulus Therapeutics and its oligonucleotide, farabursen, to bolster its renal ...

Novartis will acquire Regulus Therapeutics for up to $1.7B, boosting its kidney drug pipeline with lead candidate farabursen.

The pharma will pay $800 million for the biotech, which was launched nearly two decades ago by Alnylam and Ionis to advance ...